0.656  0.136 (26.15%)		10-09 15:27
Open: 0.51 High: 0.6897 Volume: 76,381		Pre. Close: 0.52 Low: 0.51 Market Cap: 17(M)

Short term
Mid term
Targets	6-month :	0.88	1-year :	1.02
Resists	First :	0.75	Second :	0.88
Pivot price	0.55
Supports	First :	0.57	Second :	0.46
MAs	MA(5) :	0.53	MA(20) :	0.58
	MA(100) :	0.51	MA(250) :	0.44
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	41	D(3) :	26.4
RSI	RSI(14): 57.2
52-week	High :	0.83	Low :	0.2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BTCY ] has closed below upper band by 5.5%. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.56 - 0.56	0.56 - 0.57
Low:	0.48 - 0.49	0.49 - 0.49
Close:	0.52 - 0.52	0.52 - 0.52

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Wed, 03 Sep 2025
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform - GlobeNewswire

Tue, 19 Aug 2025
Are Medical Stocks Lagging Biotricity (BTCY) This Year? - Yahoo Finance

Fri, 15 Aug 2025
Biotricity (BTCY) Upgraded to Buy: Here's Why - Nasdaq

Fri, 15 Aug 2025
Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ... - Yahoo Finance

Thu, 14 Aug 2025
Earnings call transcript: Biotricity sees positive EBITDA in Q1 2025 - Investing.com

Thu, 14 Aug 2025
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Medical - Devices
Shares Out	22 (M)
Shares Float	15 (M)
Held by Insiders	46.5 (%)
Held by Institutions	4.1 (%)
Shares Short	460 (K)
Shares Short P.Month	503 (K)

EPS	-1.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.38
Profit Margin	-117.5 %
Operating Margin	-34.9 %
Return on Assets (ttm)	-82.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	6 %
Gross Profit (p.s.)	0
Sales Per Share	0.54
EBITDA (p.s.)	-0.34
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.37
PEG Ratio	0
Price to Book value	-0.47
Price to Sales	1.17
Price to Cash Flow	-2.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.